SCIENTIFIC HUB

Araştırmanın izini sürün.

SCIENTIFIC LITERATURE · MED

Parkinson'un İlerleme İşaretleyicileri Girişimi: Parkinson Hastalığı İlerlemesini İzlemek İçin Milestone Tabanlı Bir Strateji.

Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression.

Makine çevirisi · Editoryal inceleme bekliyor

J Parkinsons Dis · 2023-01-01

DOI: 10.3233/jpd-223433PMID: 37458046

Open accessResearch Support, Non-U.S. Gov't; research-article; Journal ArticleKaynağa git ↗

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

BackgroundIdentifying a meaningful progression metric for Parkinson's disease (PD) that reflects heterogeneity remains a challenge.ObjectiveTo assess the frequency and baseline predictors of progression to clinically relevant motor and non-motor PD milestones.MethodsUsing data from the Parkinson's Progression Markers Initiative (PPMI) de novo PD cohort, we monitored 25 milestones across six domains ("walking and balance"; "motor complications"; "cognition"; "autonomic dysfunction"; "functional dependence"; "activities of daily living"). Milestones were intended to be severe enough to reflect meaningful disability. We assessed the proportion of participants reaching any milestone; evaluated which occurred most frequently; and conducted a time-to-first-event analysis exploring whether baseline characteristics were associated with progression.ResultsHalf of participants reached at least one milestone within five years. Milestones within the cognitive, functional dependence, and autonomic dysfunction domains were reached most often. Among participants who reached a milestone at an annual follow-up visit and remained active in the study, 82% continued to meet criteria for any milestone at one or more subsequent annual visits and 55% did so at the next annual visit. In multivariable analysis, baseline features predicting faster time to reaching a milestone included age (p ConclusionClinically relevant milestones occur frequently, even in early PD. Milestones were significantly associated with baseline clinical and biological markers, but not with symptomatic treatment. Further studies are necessary to validate these results, further assess the stability of milestones, and explore translating them into an outcome measure suitable for observational and therapeutic studies.

Bilimsel değerlendirme

01

Araştırma sorusu

Sorunun kapsamı orijinal çalışma üzerinden değerlendirilir.

02

Yöntem ve örneklem

Çalışma tasarımı ve örneklem için kaynak makaleyi kontrol edin.

03

Temel bulgular

Bu kayıt için editoryal olarak onaylanmış bulgu özeti henüz yayımlanmadı.

04

Sınırlılıklar

Sonuçların genellenebilirliği, yanlılık ve klinik anlamı ayrıca incelenmelidir.

Bibliyografik veriden yöntem, örneklem veya klinik sonuç çıkarımı yapılmaz.